Treatment revolution for pediatric psoriasis on horizon

BY BRUCE JANCIN

Recent spectacular advances in the treatment of adult psoriasis haven't yet reached the pediatric patient population in the United States because of an early overabundance of caution on the part of the Food and Drug Administration. But the agency has subsequently altered its stance, and the wow-factor medications are on their way, Lawrence F. Eichenfield, MD, predicted in an audio interview at the SDEF Hawaii Dermatology Seminar provided by the Global Academy for Medical Education/Skin Disease Education Foundation.

Bruce Jancin/MDedge News 

Dr. Lawrence Eichenfield


Essentially all of the more recently approved high-performance medications for adult psoriasis, including the interleukin-17 inhibitors and oral apremilast (Otezla), are now under study in adolescents, with studies in younger children likely to follow. Based upon what Dr. Eichenfield has seen of the preliminary results, a tropical tsunami of advanced treatments for pediatric psoriasis is just a couple of years away.

In the audio interview below, Dr. Eichenfield talks about the changes coming for pediatric psoriasis. 



Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego, and professor of dermatology and pediatrics, University of California, San Diego.

Dr. Eichenfield receives research grants from or serves as a consultant to a couple dozen pharmaceutical companies. The SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.